Using Continuous Glucose Monitoring to Manage Glucose and Weight in Prediabetes and Type 2 Diabetes
Continuous Glucose Monitoring for Glucose and Weight Management in Prediabetes and Non-severe Type 2 Diabetes
This study tests if using a continuous glucose monitor along with personalized diet tips and a smartphone app can help people with prediabetes and type 2 diabetes manage their blood sugar and weight better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 420 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Kangbuk Samsung Hospital Academic / other |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06542627 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of Continuous Glucose Monitoring (CGM) combined with personalized dietary education and smartphone applications to improve glucose control and weight management in individuals with prediabetes and non-severe type 2 diabetes. Participants will receive the Freestyle Libre device to monitor their glucose levels continuously. The study aims to assess how these interventions can help manage their conditions effectively in a community-based workplace setting.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 19 years old with prediabetes or non-severe type 2 diabetes.
Not a fit: Patients with type 1 diabetes, severe chronic diseases, or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to better glucose control and weight management for patients with prediabetes and type 2 diabetes.
How similar studies have performed: Other studies have shown promise in using continuous glucose monitoring for diabetes management, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects over the age of 19 * Patients with type 2 diabetes * Fasting blood glucose ≥ 126 mg/dL or * HbA1c ≥ 6.5% or * Type 2 diabetes by clinical history and treated with antidiabetic medications or lifestyle Modifications * Patients with prediabetes * Fasting blood glucose 100-125 mg/dL * HbA1c 5.7-6.4% * Willing to participate in the study Exclusion Criteria: * Subjects less than 19 years old * Patients with type 1 diabetes * Pregnant at the time of screening or planning to become pregnant during the study * Severe chronic diseases such as cancer, stroke, proliferative retinopathy, myocardial infarction, chronic renal disease, or amputation of a diabetic foot * Diagnosed with or treated for myocardial infarction, stroke, end-stage renal disease, liver failure, or chronic lung disease within the past year * Severe liver disease (e.g., cancer, liver cirrhosis, hepatitis B, hepatitis C) * Diseases of the biliary tract, thyroid disorders, autoimmune disorders, or acute infections * Planning to be admitted to a hospital within 2 months * Unable to participate in the mobile intervention study as determined by the investigator
Where this trial is running
Seoul
- Kangbuk Samsung Hospital — Seoul, South Korea (Recruiting)
Study contacts
- Study coordinator: Park
- Email: cydoctor68@gmail.com
- Phone: 0220011550
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.